NIH R01 · 2025
Vascular-targeted Atheroprotective Gene therapies to Prevent Vein Graft Failure
Autologous vein grafts (VG) are the most commonly used conduits in revascularization procedures for coronary artery disease (CAD) and peripheral arterial disease (PAD). However, VG failure rates remain high, reaching 30- 50% for lower extremity bypass and over 50% for coronary artery bypass grafts (CABG) within 5 and 10 years, respectively. Intimal hyperplasia (IH) is the primary cause of VG failure, accounting for more than 70% of cases. While medical therapies have shown some benefit in reducing CABG failure, they have not been effective in lower extremity vein bypass grafts. The pathogenesis of IH involves determinants such as endothelial injury at the time of harvest, exposure to…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.